Clinical Cancer Research (2010) 16:5892-5899

August 6, 2020

12.01.2010

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas